Welcome to your Weekly Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Halozyme to Acquire Elektrofi for Drug Delivery Expansion
Halozyme Therapeutics, Inc. announced that it has entered into a final agreement to purchase Elektrofi, Inc., a biopharmaceutical company that develops a revolutionary ultra-high concentration microparticle technology for biologics called Hypercon. The deal includes a $750 million upfront payment, along with up to three additional $50 million payments linked to regulatory clearances for certain products. Both companies’ boards of directors have approved the transaction unanimously.
Biocon Sets U.S. Launch Date for Denosumab Biosimilars
Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced that it has reached a settlement and licensing agreement with Amgen Inc. This agreement allows for the U.S. commercialization of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq). The deal resolves ongoing patent issues in the U.S. District Court for the District of New Jersey, enabling Biocon Biologics to start the U.S. launch of both products on October 1, 2025. Several terms of the agreement remain confidential.
KalVista Pharmaceuticals Appoints Bethany L. Sensenig to Board
KalVista Pharmaceuticals, Inc. announced the appointment of Bethany L. Sensenig to its Board of Directors, effective October 1, 2025. Along with joining the Board, Ms. Sensenig was named a member of the Audit Committee. In connection with this change, Nancy Stuart will step down from the Audit Committee but will remain on the Board and continue her role on the Nominating and Corporate Governance Committee. The Board also approved Ms. Stuart’s appointment to the Compensation Committee.
Interwell Health Welcomes CEO Tommy O’Connor to Accelerate Value-Based Kidney Care
Interwell Health, a leader in value-based kidney care, has appointed Tommy O’Connor as its new Chief Executive Officer. O’Connor brings extensive experience in healthcare leadership and will play a key role in furthering Interwell’s mission to transform kidney care through innovative solutions that improve patient outcomes while managing costs.
Confido Health Expands AI Voice Agents in Healthcare -Raises $10 Million
Even in 2025, 81% of patients still hit the phones to reach their doctors. For many, it means being stuck on hold, navigating confusing phone menus, or waiting days for a callback. For providers, front desks are overloaded and staffing shortages make access hard to scale. Patient frustration and staff burnout feed into each other, eroding loyalty and making every interaction harder. Confido Health is solving this problem with AI-powered voice agents built specifically for healthcare.
Iris Telehealth Appoints Healthcare Veteran David Bartley as Its First CSO
Iris Telehealth, a leading provider of virtual behavioral health services for health systems and community organizations, has appointed David Bartley as its first Chief Solutions Officer. This newly established role is aimed at driving the company’s continued expansion through technology-focused, value-based care delivery. Bartley brings more than two decades of experience in healthcare product development and strategy, with a history of leading innovation at high-growth companies. His background includes the development of patented solutions across key areas such as consumer engagement, population health, risk contracting, and revenue cycle enhancement. At Iris, Bartley will work to integrate data, advanced analytics, and scalable technology into Iris’s care delivery model, enhancing partnerships with both providers and payers.
BioLineRx and Hemispherian AS Form JV to Develop GLIX1 for Cancer
BioLineRx Ltd., a clinical-stage biopharmaceutical company that specializes in oncology and rare diseases, has joined forces with Hemispherian AS, a Norwegian biotech firm that focuses on small molecule cancer treatments, to form a joint venture. The goal is to develop GLIX1, an innovative oral small molecule designed to target the DNA damage response in glioblastoma and other types of cancer. GLIX1 works by activating TET2 in cancer cells, which causes breaks in the DNA and triggers programmed cell death, specifically in malignant cells.
OMRON Healthcare Surpasses 400 Million Blood Pressure Monitor Sales
OMRON HEALTHCARE Co., a top global leader in medical devices focused on preventive healthcare, has shared that it has sold more than 400 million blood pressure monitors around the world. This achievement shows the company’s ongoing commitment to enhancing health outcomes by making home blood pressure monitoring and preventive cardiovascular care more accessible and effective. OMRON first launched its own branded blood pressure monitor in 1973, a time when blood pressure checks were only possible in medical offices. Thanks to technological advancements, people can now easily and accurately check their blood pressure at home. OMRON Healthcare keeps pushing for innovation to better manage blood pressure and help identify serious conditions like atrial fibrillation early on.
Sky Labs Launches CART BP, a Smart Ring for 24-Hour Blood Pressure Monitoring
Sky Labs has officially launched CART BP, a new ring-shaped blood pressure monitor made for everyday use. It’s different from the usual arm cuff monitors because it’s worn on the finger and lets people track their blood pressure all day long, even while they sleep. The product has been approved by the Ministry of Food and Drug Safety (MFDS) in South Korea and uses the same tested technology as the professional CART BP Pro, which is used in hospitals for checking blood pressure over a 24-hour period.
NAVER D2SF Invests in Health Technology Startup GravityLabs
NAVER D2SF has announced a new investment in GravityLabs, a healthcare technology startup that helps users build and maintain healthy habits in a sustainable way. GravityLabs is best known for MoneyWalk, a global health platform that rewards users for tracking their daily health activities, encouraging them to be more active. This method not only helps people form long-term healthy habits but also collects a broad range of personal health data. Unlike many health apps that struggle to keep users engaged, MoneyWalk has an average daily active usage of over 30 minutes per user, showing high engagement and satisfaction.
Corey A. Collins Promoted to CEO of Tekton Research to Lead Next Era of Growth
Collins joined Tekton in December 2023 as Chief Financial Officer, bringing over 20 years of financial and operational leadership experience across the pharmaceutical and manufacturing sectors. Prior to Tekton, he held key positions at American Expediting, Dicalite Management Group and PCI Pharma Services, where he guided financial strategies that drove long-term success. His career began with financial leadership roles at GE Water & Process Technologies and Deloitte, grounding him in operational excellence and strategic vision.
Angelini Ventures Leads €12M Investment in Serenis Health
Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces it has led, alongside CDP Venture Capital as co-lead investor, a €12 million follow-on investment in Serenis, a pioneer and one of the fastest growing companies dedicated to improving access to mental health and wellbeing services in Italy.
To share your insights, please write to us at sudipto@intentamplify.com
